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BackgroundandAim.Diabetesmellitusisachronicdiseasethathasagreatimpactonpatientsandsociety.Metforminmonotherapy
is capable of maintaining a target glycemic control only for a short term. The aim of this study was to determine the eﬃcacy of
combination therapy of metformin with any antidiabetic agents in type 2 diabetes mellitus (T2DM) patients. Methods.R e p o r t s
of randomized controlled trials (RCTs) of combination therapy of metformin with various antidiabetic agents in T2DM failing
metformin alone were identiﬁed. Results. Eight studies were identiﬁed in our paper. Thiazolidinediones (TZDs) were as eﬀective
as dipeptidyl peptidase IV inhibitors (DPP IV inhs) in reducing HbA1c value (pooled mean diﬀerence −0.03%; 95% CI −0.16
to 0.10%). In comparison between TZDs and sulphonylureas (SUs), TZDs reduced fasting plasma insulin (FPI) more eﬀectively
than SUs (pool mean diﬀerence −5.72μU/mL; 95% CI −8.21 to −3.22μU/mL, P<0.00001), but no signiﬁcant diﬀerences were
detected in the eﬀects on HbA1c and fasting plasma glucose (FPG) (pooled mean diﬀerence −2.19mg/dL; 95% CI −11.32 to
6.94mg/dL, P = 0.64). Conclusions. Our study showed that TZDs reduced FPG better than did DPP IV inhs and decreased FPI
more than did SUs.
1.Introduction
Diabetes mellitus is a chronic disease that has a great
impact on patients and society. The estimate of worldwide
prevalence by the International Diabetes Federation (IDF) in
2007 is about 246 million people, most of whom (85–95%)
havetype2diabetesmellitus(T2DM)[1].Thecomplications
are the major causes of morbidity and mortality of people
with diabetes [2–4]. Antidiabetic agents have an important
role in normalizing plasma glucose levels [5, 6]. Metformin
is now recommended as the ﬁrst agent for blood glucose
lowering in type 2 diabetes patients [7–11]. Metformin has
been proven to be eﬃcacious in reducing cardiovascular
risk [12] and is the only pharmacological treatment that
could improve macrovascular outcomes in patients with
diabetes [8]. However, metformin monotherapy is capable of
maintaining a target glycemic control only for a short term
[13]. Combination therapies of metformin with other oral
antidiabetic agents are therefore necessary. There are many
therapeutic options of adding second agents in metformin-
treated subjects which are recommended [7–11], such as
insulin, insulin secretagogues, thiazolidinediones (TZDs),
glucagon-like-peptide-1 (GLP-1) analogues, and dipeptidyl
peptidase IV inhibitors (DPP IV inhs).
Our paper was aimed at determining the eﬃcacy of
combination therapy of metformin with any antidiabetic
agents in type 2 diabetes inadequately controlled with
metformin alone.
2. Methods
2.1. Search Strategy. Reports of randomized controlled trials
of combination therapy of metformin with various antidia-
betic agents in type 2 diabetes failing metformin monother-
apy were identiﬁed through a systematic literature search
of MEDLINE (Pubmed), EMBASE, and The Cochrane2 ISRN Endocrinology
Library. The following MeSH terms were used: diabetes
mellitus type 2, metformin, sulfonylurea compounds, thi-
azolidinediones, dipeptidyl peptidase IV inhibitors, insulin,
insulin NPH, and insulin long acting. This was followed by
keyword search using as keywords glibenclamide, glyburide,
gliclazide, glimepiride, glipizide, chlorpropamide, tolbu-
tamide, meglitinide, nateglinide, repaglinide, pioglitazone,
rosiglitazone, sitagliptin, vildagliptin, saxagliptin, alogliptin,
glargine, lispro, aspart, glulisine, detemir, acarbose, vogli-
bose, miglitol, exenatide, liraglutide, and pramlintide. His-
torical searches of reference lists of relevant randomized
controlled trials, systematic and narrative reviews were also
undertaken. No language restriction was imposed.
2.2. Study Selection. Eligible studies were selected by two
reviewers, and diﬀerences were resolved by agreement. The
studies were included in this systematic review, if they
(a) were randomized controlled trials in type 2 diabetes
patientswhohadalreadybeentreatedwithmetforminalone,
(b) compared between two diﬀerent antidiabetic drugs in
combination with metformin, (c) included patients with
baseline HbA1c ≥ 7%, (d) had no addition of a third oral
antidiabetic agent or insulin, (e) lasted at least 12 weeks of
treatment duration, and (f) reported outcome measure in
terms of hemoglobin A1c (HbA1c). Abstract presentations
were excluded.
We selected 12 weeks as the minimal study duration
to assure the eﬀect of medication on HbA1c level. HbA1c
at ≥7% was chosen because the recent meta-analysis of
the beneﬁt of intensive glucose-lowering treatment reported
overall HbA1c target level of <7%. Intensive glycemic
control group (HbA1c < 7%) had no signiﬁcant eﬀects on
stroke and all-cause mortality when compared with standard
treatmentwhereHbA1cgoalwas ≥7%[14].Someguidelines
recommend a target of HbA1c at ≤6.5% [7, 8, 11]. Achieving
these goals may prove diﬃcult. Only 60% of subjects have
been reported to reach an HbA1c goal of ≤7.5% [15]. In
addition, the ADA/EASD consensus treatment algorithm
for the metabolic management of diabetes recommends a
HbA1c goal at <7% [9, 10].
2.3. DataExtraction and Quality Assessment. Dataextraction
and study quality assessment were performed independently
by two investigators using a standardized form. Disagree-
ments were resolved by a third investigator. The data
extracted were publication year, study country, study design,
study duration, outcome parameters, type and dosage of
interventions, patient characteristics, and number of partici-
pants.
The methodological quality of each trial was assessed
using the scale developed by Jadad et al. [16]. The Jadad’s
scale is divided into three dimensions: randomization,
blinding and reasons for withdrawals and dropouts. The
possible maximum score is 5 points, the studies with the
score of 2 points or less are of low quality, while those with 3
points or more are of high quality.
2.4. Statistical Analysis. Primary outcome was HbA1c, sec-
ondary outcomes were fasting plasma glucose (FPG) and
fasting plasma insulin (FPI). Eﬃcacy was reported as mean
change value from baseline to ﬁnal assessment. When the
variations of these changes were not reported, we estimated
them by using the following equation: [17]
SD1(C)=

SD1(B)
2+SD1(F)
2−(2R×SD1(B)×SD1(F)),
(1)
where SD1(C) is the standard deviation of change, SD1(B)
and SD1(F) are the standard deviations of baseline and ﬁnal
values: respectively, and R is the correlation coeﬃcient and
was assumed to be 0.5. In addition, when the variations were
not reported at all, the pooled SD calculated from the studies
data that reported SD was used.
Treatment eﬀect was estimated with mean diﬀerence
in the change value between the treatment group and the
control group. The inverse variance-weighted method was
used for the pooling of mean diﬀerence and the estimation
of 95% conﬁdence interval [18]. Random eﬀects model
was used to combine the results of individual studies when
Q-statistic test was signiﬁcant at the level of 0.1 [19],
otherwise the ﬁxed eﬀects model was used [18]. I-squared
statistic which is the percentage of total variation across
studies was used to quantify the level of heterogeneity [20].
Sensitivity analysis was performed to examine the causes of
heterogeneity. Publication bias was assessed by the method
of Egger et al. [21]. The statistical analysis was undertaken
with RevMan 5.0 (Cochrane collaboration). The statistical
signiﬁcance was set at P < 0.05.
3. Results
3.1. Study Characteristics. The initial search identiﬁed 121
potentiallyrelevantrandomizedstudiesofadditionaltherapy
to metformin in type 2 diabetes mellitus. All were published
in English. One hundred and thirteen trials were excluded
for the following reasons. Seven trials were excluded as
they evaluated agents already withdraw from the market,
that is, inhaled insulin, muraglitazar, and tesaglitazar. Forty-
ﬁve trials that included subjects previously receiving various
antidiabetic regimens including metformin and did not
report data separately for each antidiabetic agent therefore
were also excluded. Thirty-three studies were excluded since
they were placebo-controlled or non-treatment-controlled.
Nine trials with entry HbA1c < 7% were excluded. We
e x c l u d e do n et r i a lw h i c ha d d e dat h i r do r a lg l u c o s e -
lowering agent or insulin. In addition, this particular trial
was previously reported in three preliminary publications
and therefore was excluded. One trial was excluded as the
duration of study was less than 12 weeks. Seven trials
were further excluded because they were duplication or
interim analysis. One trial evaluated vildagliptin 100mg
once daily which is currently not a recommended dose (the
recommended dose is now 50mg twice daily), thus it was
excluded. Six studies were abstract presentation and were
then excluded. The remaining eight trials met our inclusion
criteria and were included in the meta-analysis [22–29].
Of the eight trials, two compared thiazolidinediones
(TZDs) versus dipeptidyl peptidase IV inhibitors (DPP IVISRN Endocrinology 3
Table 1: Characteristics of the studies included in the meta-analysis.
Study, study origin Quality
score Inclusion criteria Design and
duration (week) Intervention/day n
TZDs versus DPP IV inhs.
(i) Scott et al. [22]
Australia, India, Italy,
Malaysia, New
Zealand, Poland,
Sweden
3
(i) T2DM
(ii) A1c 7–11%
(iii) Taking metformin monotherapy
≥1,500mg/day for ≥10 weeks
(iv) Aged 18–75 years
DP (18)
(i) Rosiglitazone 8mg OD +
metformin (≥1,500mg/day) usual
dose
(ii) Sitagliptin 100mg OD +
metformin (≥1,500mg/day) usual
dose
(i) 87
(ii) 94
(ii) Bolli et al. [23]
Australia, Austria,
Germany, Italy, UK,
USA, South Africa,
Spain
3
(i) T2DM
(ii) A1c 7.5–11.0%
(iii) Receiving metformin alone
≥1,500mg/day
(iv) Aged 18–77 years
(v) Male and female (non-fertile or of
childbearing potential using a
medically approved birth control
method)
(vi) BMI 22–45kg/m2
(vii) FPG < 15mmol/L
DP (52)
(i) Pioglitazone 30mg OD +
metformin (≥1,500mg/day) usual
dose
(a) mean metformin dose 2,020mg
(ii) Vildagliptin 50mg bid +
metformin (≥1,500mg/day) usual
dose
(a) mean metformin dose 2,020mg
(i) 281
(ii) 295
TZDs versus SUs
(i) Charbonnel et al.
[24]
29 European
countries, Australia,
Canada, South Africa
5
(i) T2DM
(ii) A1c 7.5–11.0%
(iii) Managed with metformin
monotherapy (≥50% of the maximum
recommended dose or maximum
tolerated dose) for ≥12 weeks
(iv) Aged 35–75 years
(v) Fasting C-peptide levels
≥0.50nmol/L (1.5ng/mL)
(vi) Stable or worsening glycemic
control for ≥3m o n t h s
DP (104)
(i) Pioglitazone 15–45mg (titrated) +
metformin (>50% maximum dose or
max-tolerated dose) usual dose
(a) Mean metformin dose 1,726mg
(b) Mean pioglitazone dose 39mg
(ii) Gliclazide 80–320mg + metformin
(>50% maximum dose or
max-tolerated dose) usual dose
(a) Mean metformin dose 1,705mg
(b) Mean gliclazide 212mg
(i) 317
(ii) 313
(ii) Garber et al. [25]
USA 4
(i) T2DM
(ii) A1c > 7.0 and ≤12.0%
(iii) On metformin monotherapy
≥1,500mg/day for ≥8w e e k s
(iv) Aged 20–78 years
(v) BMI 23–45kg/m2
(vi) Willing and able to perform
SMBG
(vii) Female of childbearing potential
had to practise acceptable methods of
birth control and to have negative
pregnancy test results within 72 hours
of study treatment
DP (24)
(i) Used metformin 1,500mg:
metformin 1,500–2,000mg (titrated)
+ rosiglitazone 4–8mg (titrated)
(ii) Used metformin >1,500mg:
metformin 2000mg + rosiglitazone
4–8mg (titrated)
(a) Mean ﬁnal metformin/
rosiglitazone dose 1,819/7.1mg
(iii) Metformin-glibenclamide
1,000–2,000/5–10mg
(a) Mean ﬁnal metformin/
glibenclamide dose 1,509/7.6mg
(i) 158
(ii) 160
(iii) Umpierrez et al.
[26]U S A 2
(i) Diagnosed of T2DM at least 6
months
(ii) A1c 7.5–10%
(iii) Treated with metformin
(1–2.5g/d) or extended-release
metformin alone (0.5–2.0g/d) for ≥8
weeks
(iv) Aged 18–79 years
(v) BMI ≥ 24kg/m2
(vi) FPG 126–235mg/dL
(vii) Fasting C-peptide ≥ 0.27nmol/L
OP (26)
(i) Pioglitazone 30–45mg (titrated) +
metformin usual dose
(a) Mean ﬁnal metformin dose
1,570mg
(ii) Glimepiride 2–8mg (titrated) +
metformin usual dose
(a) Mean ﬁnal metformin dose
1,490mg
(i) 109
(ii) 1014 ISRN Endocrinology
Table 1: Continued.
Study, study origin Quality
score Inclusion criteria Design and
duration (week) Intervention/day n
(iv) Hamann et al.
[27]E u r o p e ,M e x i c o 4
(i) Male and female with T2DM
(ii) A1c 7–10%
(iii) Having received metformin
(≥0.85g/day) for ≥8w e e k s
(iv) BMI ≥ 25kg/m2
DP (52)
(i) Rosiglitazone 4–8mg (titrated) +
metformin 2,000mg
(a) Mean ﬁnal dose of rosiglitazone/
metformin 7.7/2,000mg
(ii) Glibenclamide 5–15mg (titrated) +
metformin 2,000mg
(iii) Gliclazide 80–320mg (titrated) +
metformin 2,000mg
(a) Mean ﬁnal dose of glibenclamide/
metformin 11/2,000mg
(b) Mean ﬁnal dose of gliclazide/
metformin 238.1/2,000mg
(i) 294
(ii) 302
TZD versus TZD
(i) Derosa et al. [28]
Italy 5
(i) T2DM duration ≥6m o n t h s
(ii) A1c > 7.5% or had adverse eﬀects
with diet and metformin
(administered up to the maximum
tolerated dose)
(iii) Caucasian patients aged ≥18 years
(iv) BMI 25.0–28.1kg/m2
(v) Diagnosed with metabolic
syndrome according to the NCEP
Treatment Panel III
(vi) TG ≥ 150mg/dL
(vii) Hypertension according to the
WHO criteria (blood pressure,
≥130/≥85mmHg)
(viii) Fasting C-peptide > 1.0ng/mL
DP (48)
(i) Pioglitazone 15mg + metformin
1,500–3,000mg (titrated)
(a) Mean metformin dose 2,250 ±
750mg
(ii) Rosiglitazone 4mg OD +
metformin 1,500–3,000mg (titrated)
(a) Mean metformin dose 2,250 ±
750mg
(i) 48
(ii) 48
Insulin versus SU
(i) Kvapil et al. [29]
Croatia, Czech
Republic, Denmark,
France, Greece,
Hungary, Norway,
Poland, Portugal,
Russia, Spain
3
(i) T2DM
(ii) Receiving ≥850mg metformin
monotherapy for ≥4w e e k s
OP (16)
(i) BIAsp 30 was 0.2U/kg body weight
(could be titrated) + metformin
(maximum tolerated or maximum
eﬀective dose, titrated)
(a) Mean metformin dose 1,660mg
(ii) Glibenclamide 1.75–10.5mg
(titrated) + Metformin (maximum
tolerated or maximum eﬀective doses,
titrated)
(a) Mean metformin dose 1,660mg
(i) 116
(ii) 114
DP: double blind parallel, OP: open label parallel, BIAsp 30: biphasic insulin aspart 30, T2DM: type 2 diabetes mellitus, T1DM: type 1 diabetes mellitus,
TZDs: thiazolidinediones, Clcr: creatinine clearance, BMI: body mass index, FPG: fasting plasma glucose, SUs: sulphonylureas, Hgb: hemoglobin, SMBG:
self-monitoring blood glucose, WHO: World Health Organization, NCEP: National Cholesterol Education Program.
inhs) [22, 23], four assessed TZDs against sulphonylureas
(SUs) [24–27], the rest evaluated pioglitazone versus rosigli-
tazone [28] and biphasic insulin aspart 30 versus gliben-
clamide [29]. Characteristics of these studies are presented
in Table 1.
3.2. Eﬃcacy
3.2.1. TZDs versus DPP IV Inhs. T h e r ew e r eat o t a lo f7 5 3
T2DM patients treated with metformin in the two trials that
compared TZDs against DPP IV inhs [22, 23]. No signiﬁcant
diﬀerence in eﬀect on HbA1c was observed between TZDs
and DPP IV inhs (pooled mean diﬀerence −0.03%; 95%
CI −0.16 to 0.10%) (Table 2, Figure 1). However, TZDs
induced a greater reduction of FPG than did DPP IV inhs
(pooled mean diﬀerence −11.61mg/dL; 95% CI −17.82 to
−5.39mg/dL, P = 0.0003) (Table 3, Figure 2). Only one
trial reported FPI data [22]. FPI signiﬁcantly decreased
with TZDs compared with DPP IV inhs (mean diﬀerence
−3.50μU/mL; 95% CI −5.55 to −1.45μU/mL, P = 0.0008)
(Table 4, Figure 3).
3.2.2. TZDs versus SUs. A total of 1,711 subjects in four
studies received TZDs or SUs as an add-on to metformin
[24–27]. TZDs were no more eﬀectivethanSUsindecreasing
HbA1c (pooled mean diﬀerence 0.09%; 95% CI −0.09 to
0.26%) (Table 2, Figure 1). In addition, the same result was
observed among the FPG values. The eﬀect of TZDs inISRN Endocrinology 5
Table 2: Summary of HbA1c (%) between the treatment and the control groups.
Study
Treatment Control Diﬀerence
n Baseline Final Change n Baseline Final Change between
groups
TZDs versus DPP IV inhs.
(i) Scott et al.
[22]
Rosiglitazone
versus
Sitagliptin
87 7.73 ± 0.81 6.94 ± 0.75 −0.79 ± 0.64 91 7.75 ± 0.99 7.01 ±
0.86
−0.73 ± 0.66 −0.06
(ii) Bolli et al.
[23]
Pioglitazone
versus
Vildagliptin
295 8.48 ± 0.86
(SE = 0.05)
7.64 ± 1.89
(SE = 0.11)
−0.6 ± 1.1 280 8.4 ± 0.84
(SE = 0.05)
7.73 ±
1.34
(SE = 0.08)
−0.6 ± 1.11 0
TZDs versus SUs
(i) Charbonnel
et al. [24]
Pioglitazone
versus Gliclazide
317 8.71 ± 1.00 NA
−0.89 ± 1.29
(SE =
0.07272)
313 8.53 ± 0.89 NA
−0.77 ± 1.18
(SE =
0.06666)
−0.12
(ii) Garber et al.
[25]
Rosiglitazone
versus
Glibenclamide
152 8.43 ± 1.20 7.17 ± 1.43 −1.1 ± 1.30a 153 8.47 ± 1.25 6.70 ±
1.37
−1.5 ± 1.29a 0.4
(iii) Umpierrez
et al. [26]
Pioglitazone
versus
Glimepiride
107 8.31 ± 0.77 NA
−1.23 ± 0.76
(SE = 0.073) 96 8.40 ± 0.72 NA
−1.3 ± 0.75
(SE = 0.077) 0.07
(iv) Hamann et
al. [27]
Rosiglitazone
versus
Glibenclamide,
Gliclazide
285 8.0 ± 0.9 NA
−0.78 ± 1.01
(SE = 0.06) 288 8.0 ± 1.0 NA
−0.86 ± 1.02
(SE = 0.06) 0.08
TZD versus TZD
(i) Derosa et al.
[28]
Pioglitazone
versus
Rosiglitazone
48 8.2 ± 0.8 6.8 ± 0.3 −1.4 ± 0.7a 48 8.1 ± 0.9 6.8 ± 0.5 −1.3 ± 0.78a −0.1
Insulin versus SU
(i) Kvapil et al.
[29]
BIAsp 30 versus
Glibenclamide
108 9.24 ± 1.32
(SE = 0.127)
7.52 ± 1.09
(SE = 0.105)
−1.72 ± 1.22a 114 9.45 ± 1.39
(SE = 0.130)
7.8 ± 1.25
(SE =
0.118)
−1.65 ± 1.33a −0.07
Data are mean ± SD values. NA: not available. aSD calculated from SD baseline and ﬁnal values.
improving FPG was no better than that of SUs (pooled
meandiﬀerence −2.19mg/dL;95%CI −11.32to6.94mg/dL,
P = 0.64) (Table 3, Figure 2). On the other hand, TZDs
decreased FPI greater than did SUs (pool mean diﬀerence
−5.72μU/mL; 95% CI −8.21 to −3.22μU/mL, P<0.00001)
(Table 4, Figure 3). No publication bias was detected in
comparing TZDs with SUs in terms of HbA1c (Egger bias
4.17; 95% CI −11.82 to 20.16, P = 0.38) (Figure 4).
3.2.3. TZDs versus TZDs. One trial that compared piogli-
tazone versus rosiglitazone and involved 96 subjects [28]
showed no diﬀerences in eﬀects on HbA1c (mean diﬀerence
−0.10%; 95% CI −0.40 to 0.20%) (Table 2, Figure 1),
FPG (mean diﬀerence −3.00mg/dL; 95% CI −11.98 to
5.98mg/dL) (Table 3, Figure 2), and FPI (mean diﬀerence
–1.40μU/mL; 95% CI −3.64 to 0.84μU/mL) (Table 4,
Figure 3).6 ISRN Endocrinology
Study or subgroup
1.1.1 TZD versus DPP IV inh
Bolli 2009
Scott 2008
Subtotal (95% CI)
1.1.2 TZD versus SU
Charbonnel 2005
Garber 2006
Hamann 2008
Umpierrez 2006
Subtotal (95% CI)
1.1.3 TZD versus TZD
Derosa 2006
Subtotal (95% CI)
Heterogeneity: Not applicable
1.1.4 Insulin versus SU
Kvapil 2006
Subtotal (95% CI)
Heterogeneity: Not applicable
Mean SD
1.1
0.64
1.29
1.3
1.01
0.76
0.7
1.22
Total
295
87
382
317
152
285
107
861
48
48
108
108
Mean SD
1.11
0.66
1.18
1.29
1.02
0.75
0.78
1.33
Total
280
91
371
313
153
288
96
850
48
48
114
114
Weight
52.8%
47.2%
26.6%
25.3%
IV, random, 95% CI
0.4 [0.11, 0.69]
Treatment Control Mean difference Mean difference
IV, random, 95% CI
0 0.25 0.5
Favours treatment Favours control
−0.5 −0.25
−0.6
−0.79
−0.6
−0.73 −0.06 [−0.25, 0.13]
Test for overall eﬀect: Z = 0.42 (P = 0.67)
Heterogeneity: τ2 = 0; χ2 = 0.2, df = 1( P = 0.65); I2 = 0%
Heterogeneity: τ2 = 0.02; χ2 = 8.66, df = 3( P = 0.03); I2 = 65%
Test for overall eﬀect: Z = 0.94 (P = 0.35)
Test for overall eﬀect: Z = 0.66 (P = 0.51)
Test for overall eﬀect: Z = 0.41 (P = 0.68)
−0.89
−1.1
−0.78
−1.23
−0.77
−1.5
−0.86
−1.3
−0.12 [−0.31, 0.07]
0.08 [−0.09, 0.25]
0.07 [−0.14, 0.28]
0.09 [−0.09, 0.26]
−1.4 −1.3
−1.72 −1.65 −0.07 [−0.41, 0.27]
−0.07 [−0.41, 0.27]
−0.1 [−0.4, 0.2]
−0.1 [−0.4, 0.2]
100%
19%
29%
100%
100%
100%
100%
100%
0 [−0.18, 0.18]
−0.03 [−0.16, 0.1]
Figure 1: Eﬀects of various antidiabetic agents on HbA1c as an add-on treatment to metformin in T2DM.
3.2.4. Insulin versus SUs. One study examined the eﬀect of
biphasic insulin aspart 30 (n = 108) against glibenclamide
(n = 114) [29]. There was no signiﬁcant diﬀerence in eﬀect
onHbA1cbetweenthetwogroups(meandiﬀerence−0.07%;
95% CI −0.41 to 0.27%).
4. Discussion
The results of this analysis suggest that TZDs were as
eﬀective as DPP IV inhs in reducing HbA1c value in type
2 diabetes patients who had been treated with metformin
alone, however, FPG better improved with TZDs than with
DPP IV inhs. From its mechanism of actions, TZDs may
reduce FPI more than does DPP IV inhs. In addition, there
are some issues that should be concerned. First, patients in
both trials received ﬁxed-dose TZDs (rosiglitazone 8mg/day
[22], pioglitazone 30mg/day [23]) and there was no re-
titration. Indeed, dose of TZDs in combination therapy
with metformin should be titrated from initial dose to the
maximum dose (rosiglitazone 4–8mg/day, pioglitazone 15–
45mg/day) based on eﬃcacy in reducing hyperglycaemia
and tolerability such as side eﬀects. Second, maximum dose
of TZD was not used (pioglitazone 30mg OD was used)
whiles maximum recommended dose of the DPP IV inh
(vildagliptin 50mg bid) was used in one trial and patients
compliance was not determined [23]. That may aﬀect the
comparability between the comparators.
TZDs reduced FPI more eﬀectively than SUs, but
no signiﬁcant diﬀerences were detected in the eﬀects on
HbA1c and FPG. All subjects in the included studies had
hyperinsulinemia (Table 4). Hyperinsulinemia is recog-
nized as a risk factor that aﬀects the development and
progression of atherosclerosis and cardiovascular disease
which are the major causes of morbidity and mortality
in diabetes patients [30]. TZDs improve glycaemic con-
trol by promoting the local eﬀect of insulin. TZDs also
decrease the gluconeogenesis from hepatic tissues, resulting
in reduced insulin resistance, which leads to improved
glycemic control with no enhancement in the insulin
secretion. [31], while SUs improve blood glucose level by
triggering insulin release from the pancreatic β-cell [32].
Thus, TZDs and SUs may have similar eﬀect in control-
l i n gb l o o dg l u c o s el e v e lb u th a v ed i ﬀerent eﬀect on FPI
level.ISRN Endocrinology 7
Study or subgroup
1.2.1 TZD versus DPP IV inh
Bolli 2009
Scott 2008
Subtotal (95% CI)
1.2.2 TZD versus SU
Charbonnel 2005
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Table 3: Summary of FPG (mg/dL) between the treatment and the control groups.
Study
Treatment Control Diﬀerence
n Baseline Final Change n Baseline Final Change between
groups
TZDs versus DPP IV inhs.
(i) Scott et al.
[22]
Rosiglitazone
versus
Sitagliptin
87 156.9 ± 31.6 132.8 ± 29.9 −24.5 ± 33.55 92 157.2 ± 30.7 145.8 ±
35.3
−11.7 ± 33.52 −12.8
(ii) Bolli et al.
[23]
Pioglitazone
versus
Vildagliptin
295
198.20 ±
48.65
(11.0 ±
2.7mmol/L)
NA
−28.83 ± 48.95
(−1.6mmol/L) 280
198.40 ±
46.85
(11.3 ±
2.6mmol/L)
NA
−18.02 ± 49.22
(−1.0mmol/L)
−10.81
TZDs versus SUs
(i) Charbonnel
et al. [24]
Pioglitazone
versus Gliclazide
317
212.61 ±
55.86
(11.8 ±
3.1mmol/L)
NA
−32.43 ± 59.28
(−1.8 ± 0.18
(SE) mmol/L)
313
203.60 ±
46.85
(11.3 ±
2.6mmol/L)
NA
−19.82 ± 57.30
(−1.1 ± 0.18
(SE) mmol/L)
−12.61
(ii) Garber et al.
[25]
Rosiglitazone
versus
Glibenclamide
152 188.95 ±
36.32
151.05 ±
43.16
−36 ± 40.18a 153 193.68 ±
34.21
143.27 ±
46.16
−46 ± 41.50a 10
(iii) Umpierrez
et al. [26]
Pioglitazone
versus
Glimepiride
107 184.2 ± 42.14 NA
−39.7 ± 35.38
(SE = 3.42) 96 180.4 ± 38.72 NA
−34.1 ± 35.57
(SE = 3.63)
−5.6
(iv) Hamann et
al. [27]
Rosiglitazone
versus
Glibenclamide,
Gliclazide
285
189.19 ±
50.45
(10.5 ±
2.8mmol/L)
NA
−41.26 ± 48.67
(−2.29 ± 0.16
(SE) mmol/L)
288
183.78 ±
52.25
(10.2 ±
2.9mmol/L)
NA
−40.54 ± 48.92
(−2.25 ± 0.16
(SE) mmol/L)
−0.72
TZD versus TZD
(i) Derosa et al.
[28]
Pioglitazone
versus
Rosiglitazone
48 161 ± 24 140 ± 15 −21 ± 21a 48 164 ± 27 146 ± 18 −18 ± 23.81a −3
Data are mean ± SD values. NA: not available. aSD calculated from SD baseline and ﬁnal values. To convert mg/dL to mmol/L multiply by 0.0555.
Evidence of interstudy heterogeneity was discovered in
the comparison of TZDs against SUs based on HbA1c
(χ2 = 8.66, P = 0.03; I2 = 65%, Figure 1). Similar results
were found with FPG outcome (χ2 = 12.42, P = 0.006;
I2 = 76%) and FPI parameter (χ2 = 16.23, P = 0.001;
I2 = 82%). Sensitivity analysis was performed by excluding
Garber’s study [25] which was diﬀerent from other studies in
various aspects. Firstly, it lasted only 24 weeks, the shortest
treatment duration among the trials that compared TZDs
against SUs. Hence, TZD may not demonstrate maximum
eﬀectiveness in reducing hyperglycemia that was supported
by ADOPT trial in which TZDs showed the maximum
beneﬁt in decreasing HbA1c at 48 week [33]. Secondly,
the dose of metformin could be up- and downtitrated,
while other trials used metformin at baseline dose and
maintained the dose throughout the course of studies.
Finally, the medication could be titrated at every visit (4
week thereafter for 24 weeks) depending on mean daily
glucose or fructosamine levels, while other trials employed
restriction of forced-titration period (approximately 1 to
16 weeks). When this study was excluded, no signiﬁcant
heterogeneity was observed with regard to HbA1c (χ2 =
2.74, P = 0.25; I2 = 27%) and FPG results (χ2 = 3.70,
P = 0.16; I2 = 46%). The eﬀect estimates remained
unchanged. The pooled mean diﬀerences were 0.01% (95%
CI −0.11 to 0.14%) and −6.06mg/dL (95% CI −13.08
to 0.95mg/dL), respectively for HbA1c and FPG values.
Interstudy heterogeneity in the pooling of FPI may beISRN Endocrinology 9
Table 4: Summary of FPI (μU/mL) between the treatment and the control groups.
Study
Treatment Control Diﬀerence
n Baseline Final Change n Baseline Final Change between
groups
TZD versus DPP IV inh.
(i) Scott et al.
[22]
Rosiglitazone
versus
Sitagliptin
73 15.1 ± 9.6 11.2 ± 8.8 −3.7 ± 6.54 79 14.7 ± 9.9 14.5 ± 8.6 −0.2 ± 6.35 −3.5
TZDs versus SUs
(i) Charbonnel
et al. [24]
Pioglitazone
versus Gliclazide
317 15.3 ± 11.70 NA
−2.61 ± 10.48b
(−18.1pmol/L) 313 15.0 ± 10.07 NA 1.90 ± 10.48b
(13.2pmol/L)
−4.51
(ii) Garber et al.
[25]
Rosiglitazone
versus
Glibenclamide
152 18 ± 11 NA −7 ± 10.48b 153 15 ± 11 NA −3 ± 10.48b −4
(iii) Umpierrez
et al. [26]
Pioglitazone
versus
Glimepiride
107 16.9 ± 15.2 NA
−5.18 ± 11.90
(SE = 1.15) 96 14.8 ± 8.95 NA 6.21 ± 11.95
(SE = 1.22)
−11.39
(iv) Hamann et
al. [27]
Rosiglitazone
versus
Glibenclamide,
Gliclazide
236
12.40 ± 10.56
(86.12 ±
73.34pmol/L)
8.26 ± 5.78
(57.36 ±
40.13pmol/L)
−4.14 ± 9.16a 229
11.83 ± 11.38
(82.15 ±
79.04pmol/L)
11.95 ± 8.95
(82.98 ±
62.15pmol/L)
0.12 ± 10.38a −4.26
TZD versus TZD
(i) Derosa et al.
[28]
Pioglitazone
versus
Rosiglitazone
48 25.5 ± 6.1 20.2 ± 4.9 −5.3 ± 5.60a 48 26.1 ± 5.9 22.2 ± 5.2 −3.9 ± 5.58a 1.4
Data are mean ± SD values. NA: not available. aSD calculated from SD baseline and ﬁnal values. bSD calculated from pooled standard deviation of Umpierrez
et al. [26] and Hamann et al. [27].T oc o n v e r tμU/mL to pmol/L multiply by 6.945.
attributable to the study by Umpierrez G et al. 2006 [26].
In this study, the patients in the SU group had higher
body mass index (BMI) (mean 34.5kg/m2) compared with
those reported in other studies (mean 32.5kg/m2). Excess
body weight was shown to be directly correlated with
hyperinsulinemia [33], thus reduced eﬀect on FPI in the
SU group. Sensitivity analysis conducted by excluding this
trial revealed no signiﬁcant heterogeneity (χ2 = 0.13, P =
0.94; I2 = 0%). The eﬀect of TZDs remained unaﬀected.
FPI signiﬁcantly reduced with TZDs compared with SUs
(pooled mean diﬀerence −4.31μU/mL; 95% CI −5.39 to
−3.24μU/mL, P<0.00001).
We found that our results contrasted with those pre-
viously reported by Monami et al. 2008 [34]w h e r e
SUs demonstrated a greater eﬃcacy in reducing HbA1c
compared with TZDs. Monami results were based on clinical
trials up to and including January 2007.
There were variations and limitations among the
included studies. Several treatment strategies including diet
control, exercise training, and antidiabetic agents are useful
tools to improve glycaemic control in diabetes. Only two
studies provided details about dietary advice [24, 25].
There were variations in criteria for dose titration. Garber
et al. [25] titrated study medication according to mean
daily glucose levels measured by self-monitoring of blood
glucose (SMBG) method or fructosamine levels. In addition,
downward titration was permitted only in glibenclamide-
arm [25]. While in other trials, the study medications were
titrated to higher or lower doses based on tolerability, such
as actual hypoglycemia or enhanced risk of hypoglycemia
[24]. Umpierrez et al. [26] administered active agent with
forced titration to a maximum dose or adjusted dose based
on fasting SMBG. However, only pioglitazone treatment
was uptitrated based on HbA1c levels [26]. Down- and10 ISRN Endocrinology
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Figure 4: Funnel plot of the studies included in the comparison of
TZDs versus SUs.
uptitrating the dose were also performed according to mean
daily glucose from SMBG results [27]. Furthermore, the
duration allowed for the dose titration also varied among
the included trials. Most trials had limited period for dose
titration and maintained that dose until the end of study
except the study by Garber et al. in which the dose could
be increased or decreased every 4 weeks throughout 24-week
study duration [25]. In the other trial, duration for dose
titration diﬀered between the intervention and the control
groups [26].
The methodological quality of the included studies was
assessed by Jadad’s score. Studies scoring 3 or greater were
rated as high quality trials [16]. Of the eight trials, seven
[22–25, 27–29] were rated as high quality. One study was
not double-blind study and did not report the method to
generate allocation and the reasons for dropout [26].
A statistical pooling of pioglitazone versus rosiglitazones
and biphasic insulin aspart 30 versus glibenclamide was
not possible. However, in both trials, there were no sig-
niﬁcant diﬀerences between the treatment and the control
groups in all outcomes. This may be explained by the fact
that pioglitazone and rosiglitazone are categorized in the
same glucose-lowering agent group. In comparison between
biphasic insulin aspart 30 and glibenclamide, the initial
dose of biphasic insulin aspart 30 was 0.2U/kg/day and the
dose was titrated every one to seven days in step of two to
four units per injection. Thus, patients whose blood glucose
levels were uncontrolled with suggested dose and required
additional dose were absolutely not able to achieve target
glycaemic goals.
5. Conclusions
TZDs, DPP IV inhs, and SUs may have similar eﬀect
in reducing HbA1c in type 2 diabetes patients whose
blood glucose levels were not adequately controlled with
metformin alone. However, TZDs decreased FPG better
than did DPP IV inhs and reduced FPI more than did
SUs. Given the limitations of the published data, large
sample size, high quality, randomized controlled trials of
combinationtreatmentwithmetformin,andotheragentsare
warranted.
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